We are live on ! Find out more
HRTX icon

Heron Therapeutics
HRTX

100 hedge funds and large institutions have $1.07B invested in Heron Therapeutics in 2017 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 49 increasing their positions, 15 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

227% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 15

56% more capital invested

Capital invested by funds: $690M → $1.07B (+$385M)

50% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 16

1% more funds holding

Funds holding: 99 → 100 (+1)

0.64% less ownership

Funds ownership: 134.39% → 133.75% (-0.64%)

19% less call options, than puts

Call options by funds: $1.36M | Put options by funds: $1.68M

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

Holders
100
Holders Change
+1
Holders Change %
+1.01%
% of All Funds
2.49%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.1%
New
24
Increased
49
Reduced
15
Closed
16
Calls
$1.36M
Puts
$1.68M
Net Calls
-$323K
Net Calls Change
-$13M

Top Buyers

1
BlackRock
BlackRock
New York
+$36.7M
2
TCM
Tang Capital Management
California
+$34M
3
Invesco
Invesco
Georgia
+$31.9M
4
CC
Carlson Capital
Texas
+$30.5M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$29.9M

Top Sellers

1
CAM
Cormorant Asset Management
Massachusetts
-$10.4M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$6.73M
3
VMI
VHCP Management II
New York
-$5.32M
4
Millennium Management
Millennium Management
New York
-$3.37M
5
EAM
Eventide Asset Management
Massachusetts
-$2.95M
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
101
Susquehanna International Group
Pennsylvania
– -$6.73M -485,927 Closed
VMI
102
VHCP Management II
New York
– -$5.32M -405,901 Closed
Millennium Management
103
Millennium Management
New York
– -$3.37M -257,062 Closed
EAM
104
Eventide Asset Management
Massachusetts
– -$2.95M -225,000 Closed
HT
105
HAP Trading
New York
– -$2.02M -154,035 Closed
AGC
106
Alden Global Capital
Florida
– -$864K -65,935 Closed
Squarepoint
107
Squarepoint
New York
– -$478K -36,467 Closed
TI
108
Trexquant Investment
Connecticut
– -$353K -26,915 Closed
HCM
109
Highbridge Capital Management
New York
– -$206K -15,697 Closed
NIT
110
NumerixS Investment Technologies
British Columbia, Canada
– -$155K -11,800 Closed
Simplex Trading
111
Simplex Trading
Illinois
– -$28.6K -2,067 Closed
GWM
112
Geneos Wealth Management
Colorado
– -$8K -679 Closed
NFG
113
Next Financial Group
Texas
– -$3K -200 Closed
SFS
114
Sowell Financial Services
Arkansas
– -$1K -50 Closed
US Bancorp
115
US Bancorp
Minnesota
– -$1K -41 Closed
1 2 3 4
5

HRTX Hedge Fund Activity: Q1 2017 in Review

100 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q1 2017, worth a combined $1.07B — up 56% from $690M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new HRTX positions and 16 closed out — a net gain of 8 holders — while 49 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $36.7M. The largest seller was Cormorant Asset Management, cutting an estimated $10.4M.

  • 100 institutional investors held Heron Therapeutics (HRTX) as of Q1 2017, up from 99 in Q4 2016.
  • Funds reported $1.07B of Heron Therapeutics stock for Q1 2017, up 56% quarter-over-quarter.
  • 24 funds opened new Heron Therapeutics positions in Q1 2017 and 16 closed out, a net change of +8 holders.
  • The largest Heron Therapeutics buyer in Q1 2017 was BlackRock, an estimated $36.7M added.
  • The largest Heron Therapeutics seller in Q1 2017 was Cormorant Asset Management, an estimated $10.4M sold.

Based on aggregated 13F filings for Q1 2017.